Printer Friendly

TELIOS SUBMITS PMA FOR TELIO-DERM(R) WOUND HEALING AGENT

 SAN DIEGO, March 25 /PRNewswire/ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) announced today that it has submitted a Pre-Market Approval application ("PMA") to the U.S. Food and Drug Administration ("FDA") for its first product, Telio-Derm(R) wound healing agent, for the treatment of chronic dermal ulcers associated with diabetes.
 Telio-Derm(R) wound healing agent is based on a peptide containing the cell adhesion sequence, RGD (arginine-glycine-aspartic acid), formulated in a gel with hyaluronic acid. Telio-Derm(R) is designed to provide a provisional matrix that allows cells to move rapidly into the void of the wound and to build new tissue in an accelerated and organized manner.
 The PMA filing is based on the statistically significant results of a multicenter, randomized, placebo-controlled, prospective clinical trial in patients with diabetic foot ulcers. This study showed a fourfold increase in the number of ulcers completely healed in the Telio-Derm(R) group compared to the control group. There was also a statistically significant improvement in the rate of healing for Telio-Derm(R) treated patients.
 An estimated 1 million diabetics in the United States will develop chronic dermal ulcers, usually occurring on their feet, which often result in serious complications such as amputation and life- threatening infections. Medical costs for treatment of these patients are high because of prolonged hospitalization, long-term antibiotic therapy, surgery, and physical therapy. Approval of the PMA by the FDA is required before the Telio-Derm(R) wound healing agent can be marketed.
 Telios is a leader in the development of a new class of therapeutic products that modify or mimic extracellular matrix functions in tissue repair and disease. The company is applying its proprietary technology to develop products for the treatment of other types of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases (such as certain kidney diseases), cardiovascular disease, and osteoporosis.
 -0- 3/25/93
 /CONTACT: Audrey D. Keane, director of corporate development of Telios Pharmaceuticals, 619-622-2615/
 (TLIO)


CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU:

JL-KJ -- SD008 -- 9884 03/25/93 20:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 25, 1993
Words:337
Previous Article:CREDIT LYONNAIS, S.A. RETAINS CREATIVE ARTISTS AGENCY, AS CONSULTANT
Next Article:JENNY CRAIG INC. RESPONDS TO FTC DECISION TO DENY PETITION
Topics:


Related Articles
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
TELIOS ANNOUNCES SECOND QUARTER 1992 RESULTS
LIFE TECHNOLOGIES INC. ACQUIRES ASSETS OF RESEARCH PRODUCTS DIVISION OF TELIOS PHARMACEUTICALS INC.
LEADING RESEARCHERS REPORT THAT TP-9201 PREVENTS BLOOD CLOTTING WITHOUT INCREASING BLEEDING TIME
TELIOS PHARMACEUTICALS SIGNS AN AGREEMENT WITH LILLY TO DEVELOP NOVEL OSTEOPOROSIS THERAPEUTICS
TELIOS ANNOUNCES FIRST QUARTER 1993 RESULTS
Integra LifeSciences Receives Nearly $600,000 in Grants
Ortec Completes Patient Enrollment for Confirmatory Trial Evaluating OrCel(R) in Healing Venous Leg Ulcers.
Ortec Announces Positive Results in Confirmatory Venous Leg Ulcer Trial.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters